This database contains 104 studies, archived under the term: "prospective studies"
Click here to filter this large number of results.
Effects of general practitioner training and family support services on the care of home-dwelling dementia patients–results of a controlled cluster-randomized study
Donath, Carolin,
Grässel, Elmar,
Grossfeld-Schmitz, Maria,
Menn, Petra,
Lauterberg, Jörg,
Wunder, Sonja,
Marx, Peter,
Ruckdäschel, Stephan,
Mehlig, Hilmar,
Holle, Rolf
Background: More than 90% of dementia patients are cared for by their general practitioners, who are decisively involved in the diagnosis, therapy and recommendation of support services.; Objective: To test whether special training of general practitioners alters the care of dementia patients through their systematic recommendation of caregiver counseling and support groups.; Method: 129 general […]
Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study
Wroolie, T. E.,
Kenna, H. A.,
Williams, K. E.,
Powers, B. N.,
Holcomb, M.,
Lazzeroni, L.,
Rasgon, N. L.
Background: To determine the effects of memantine on cognition in a normal population of postmenopausal women with putative risk factors for Alzheimer’s disease (AD) using a built-in control for the genetic risk factor for AD (apoE-epsilon4 status).; Methods: A prospective, open-label, 6-month pilot medication trial with memantine and follow-up after discontinuance conducted at the Center […]
Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer’s disease
Sadowsky, Carl H.,
Dengiz, Alan,
Olin, Jason T.,
Koumaras, Barbara,
Meng, Xiangyi,
Brannan, Stephen
Objective: Evaluate safety and tolerability of switching from donepezil to rivastigmine transdermal patch in patients with mild to moderate Alzheimer’s disease.; Methods: Prospective, parallel-group, open-label study to evaluate immediate or delayed switch from 5-10 mg/day donepezil to 4.6 mg/24 h rivastigmine following a 4-week treatment period.; Results: Rates of discontinuation due to any reason or […]
Long-term rivastigmine treatment in a routine clinical setting
Objective: The aim of the study was to observe the effects of long-term rivastigmine treatment in patients with mild to moderate Alzheimer’s disease (AD) in a routine clinical setting.; Methods: This was a prospective, open-label, observational, multicentre, non-randomized study. Outcome measures included the Mini Mental State Examination (MMSE), the Clinician’s Interview-Based Impression of Change (CIBIC) […]
Effectiveness of a psychoeducational intervention program in the reduction of caregiver burden in Alzheimer’s disease patients’ caregivers
Martín-Carrasco, Manuel,
Martín, Manuel Franco,
Valero, Carmelo Pelegrín,
Millán, Pedro Roy,
García, Celso Iglesias,
Montalbán, Salvador Ros,
Vázquez, Ana Luisa Gobartt,
Piris, Sonia Pons,
Vilanova, Montserrat Balañá
Objectives: Caregivers of patients with Alzheimer’s disease (AD) experience physical and psychological stress due to the caring experience. This study evaluated the benefits of a Psychoeducational Intervention Program (PIP) on caregiver burden in southern Europe.; Methods: A multicentre, prospective, randomised study was conducted. One hundred and fifteen caregivers of patients with clinical diagnosis of AD […]
Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental
Lloret, Ana,
Badía, Mari-Carmen,
Mora, Nancy J.,
Pallardó, Federico V.,
Alonso, Maria-Dolores,
Viña, Jose
There is controversy as to whether vitamin E is beneficial in Alzheimer’s disease (AD). In this study, we tested if vitamin E prevents oxidative stress and loss of cognition in AD. Fifty-seven AD patients were recruited and divided in two groups: placebo or treated with 800 IU of vitamin E per day for six months. […]
Disclosure of APOE genotype for risk of Alzheimer’s disease
Green, Robert C.,
Roberts, J. Scott,
Cupples, L. Adrienne,
Relkin, Norman R.,
Whitehouse, Peter J.,
Brown, Tamsen,
Eckert, Susan LaRusse,
Butson, Melissa,
Sadovnick, A. Dessa,
Quaid, Kimberly A.,
Chen, Clara,
Cook-Deegan, Robert,
Farrer, Lindsay A.
Background: The apolipoprotein E (APOE) genotype provides information on the risk of Alzheimer’s disease, but the genotyping of patients and their family members has been discouraged. We examined the effect of genotype disclosure in a prospective, randomized, controlled trial.; Methods: We randomly assigned 162 asymptomatic adults who had a parent with Alzheimer’s disease to receive […]
Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer’s disease: a prospective, observational study
Santoro, Aurelia,
Siviero, Paola,
Minicuci, Nadia,
Bellavista, Elena,
Mishto, Michele,
Olivieri, Fabiola,
Marchegiani, Francesca,
Chiamenti, Andrea Maria,
Benussi, Luisa,
Ghidoni, Roberta,
Nacmias, Benedetta,
Bagnoli, Silvia,
Ginestroni, Andrea,
Scarpino, Osvaldo,
Feraco, Emidio,
Gianni, Walter,
Cruciani, Guido,
Paganelli, Roberto,
Di Iorio, Angelo,
Scognamiglio, Mario,
Grimaldi, Luigi Maria Edoardo,
Gabelli, Carlo,
Sorbi, Sandro,
Binetti, Giuliano,
Crepaldi, Gaetano,
Franceschi, Claudio
Acetylcholinesterase inhibitors (AChEIs) have been used to improve cognitive status and disability in patients with mild to moderate Alzheimer’s disease (AD). However, while the efficacy of AChEIs (i.e. how they act in randomized controlled trials) in this setting is widely accepted, their effectiveness (i.e. how they behave in the real world) remains controversial. To compare […]
The obesity related gene, FTO, interacts with APOE, and is associated with Alzheimer’s disease risk: a prospective cohort study
Keller, Lina,
Xu, Weili,
Wang, Hui-Xin,
Winblad, Bengt,
Fratiglioni, Laura,
Graff, Caroline
The FTO gene has been shown to have a small but robust effect on body mass index (BMI) and to increase the risk for diabetes. Both high BMI and diabetes are vascular risk factors that might play a role in the development of Alzheimer’s disease (AD) and dementia. Thus, our aim was to explore the […]